{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:44:18Z","timestamp":1794440658874,"version":"4.9.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T00:00:00Z","timestamp":1541376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T00:00:00Z","timestamp":1541376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High-dose melphalan with autologous stem cell transplantation (ASCT) can induce durable haematological and organ responses in systemic AL amyloidosis (AL). Stringent selection criteria have improved safety of ASCT in AL but most patients are transplant-ineligible. We report our experience of deferred ASCT in AL patients who were transplant-ineligible at presentation but had improvements in organ function after induction chemotherapy, enabling them to undergo ASCT. Twenty-two AL patients underwent deferred ASCT from 2011 to 2017. All had serial organ function and clonal response assessment. Organ involvement and responses were defined by amyloidosis consensus criteria. All patients were transplant-ineligible at presentation, predominantly due to advanced cardiac involvement. All received bortezomib-based therapy, with 100% haematologic response (86% complete response (CR)\/very good partial response (VGPR)), enabling reversal of ASCT exclusion criteria. Patients underwent deferred ASCT for haematologic progression (45%) or consolidation (55%). There was no transplant-related mortality. Haematologic responses post-ASCT: CR 50%, VGPR 27%, PR 18%, non-response 5%. In all, 85.7% achieved cardiac responses. Median overall survival (OS) was not reached. Median progression-free survival (PFS) was 54 months. This selected cohort achieved excellent haematologic responses, organ responses, PFS and OS with deferred ASCT. If larger studies confirm these findings, this may widen the applicability of ASCT in AL.<\/jats:p>","DOI":"10.1038\/s41408-018-0137-9","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T18:24:03Z","timestamp":1541442243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Deferred autologous stem cell transplantation in systemic AL amyloidosis"],"prefix":"10.1038","volume":"8","author":[{"given":"Richa","family":"Manwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Hegenbart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shameem","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajitha","family":"Sachchithanantham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampia","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwee","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Dittrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kimmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Sch\u00f6nland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Wechalekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,5]]},"reference":[{"key":"137_CR1","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","volume":"126","author":"V Sanchorawala","year":"2015","unstructured":"Sanchorawala, V. et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood 126, 2345\u20132347 (2015).","journal-title":"Blood"},{"key":"137_CR2","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","volume":"33","author":"A D\u2019Souza","year":"2015","unstructured":"D\u2019Souza, A. et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study. J. Clin. Oncol. 33, 3741\u20133749 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"1 Suppl 1","key":"137_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bbmt.2007.10.026","volume":"14","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri, A., Merlini, G. & Comenzo, R. L. Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego). Biol. Blood. Marrow Transplant. 14(1 Suppl 1), 6\u201311 (2008).","journal-title":"Biol. Blood. Marrow Transplant."},{"key":"137_CR4","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","volume":"31","author":"TV Kourelis","year":"2013","unstructured":"Kourelis, T. V. et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J. Clin. Oncol. 31, 4319\u20134324 (2013).","journal-title":"J. Clin. Oncol."},{"key":"137_CR5","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1046\/j.1365-2141.1998.00772.x","volume":"101","author":"P Moreau","year":"1998","unstructured":"Moreau, P. et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br. J. Haematol. 101, 766\u2013769 (1998).","journal-title":"Br. J. Haematol."},{"key":"137_CR6","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1200\/JCO.2017.76.9554","volume":"36","author":"MH Sidiqi","year":"2018","unstructured":"Sidiqi, M. H. et al. Stem cell transplantation for light chain amyloidosis: decreased early mortality over time. J. Clin. Oncol. 36, 1323\u20131329 (2018).","journal-title":"J. Clin. Oncol."},{"key":"137_CR7","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3324\/haematol.2014.104109","volume":"99","author":"A Jaccard","year":"2014","unstructured":"Jaccard, A. et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica 99, 1479\u20131485 (2014).","journal-title":"Haematologica"},{"key":"137_CR8","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","volume":"28","author":"E Kastritis","year":"2010","unstructured":"Kastritis, E. et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J. Clin. Oncol. 28, 1031\u20131037 (2010).","journal-title":"J. Clin. Oncol."},{"key":"137_CR9","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","volume":"119","author":"CP Venner","year":"2012","unstructured":"Venner, C. P. et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 119, 4387\u20134390 (2012).","journal-title":"Blood"},{"key":"137_CR10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.clml.2014.02.003","volume":"14","author":"EC Scott","year":"2014","unstructured":"Scott, E. C. et al. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study. Clin. Lymphoma Myeloma Leuk. 14, 424\u201330.e1 (2014).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"137_CR11","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/bmt.2015.73","volume":"50","author":"RF Cornell","year":"2015","unstructured":"Cornell, R. F. et al. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. Bone Marrow Transplant. 50, 914\u2013917 (2015).","journal-title":"Bone Marrow Transplant."},{"key":"137_CR12","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/bmt.2015.326","volume":"51","author":"S Hong","year":"2016","unstructured":"Hong, S. et al. Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy. Bone Marrow Transplant. 51, 732\u2013734 (2016).","journal-title":"Bone Marrow Transplant."},{"key":"137_CR13","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","volume":"119","author":"JR Mikhael","year":"2012","unstructured":"Mikhael, J. R. et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 119, 4391\u20134394 (2012).","journal-title":"Blood"},{"key":"137_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz, M. A. et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am. J. Hematol. 79, 319\u2013328 (2005).","journal-title":"Am. J. Hematol."},{"key":"137_CR15","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/leu.2012.100","volume":"26","author":"RL Comenzo","year":"2012","unstructured":"Comenzo, R. L. et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 26, 2317\u20132325 (2012).","journal-title":"Leukemia"},{"key":"137_CR16","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini, G. et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J. Clin. Oncol. 30, 4541\u20134549 (2012).","journal-title":"J. Clin. Oncol."},{"key":"137_CR17","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","volume":"121","author":"AD Wechalekar","year":"2013","unstructured":"Wechalekar, A. D. et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 121, 3420\u20133427 (2013).","journal-title":"Blood"},{"key":"137_CR18","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal, M. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N. Engl. J. Med. 376, 1311\u20131320 (2017).","journal-title":"N. Engl. J. Med."},{"key":"137_CR19","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.3324\/haematol.2014.108191","volume":"99","author":"CP Venner","year":"2014","unstructured":"Venner, C. P. et al. Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting. Haematologica 99, e260\u2013e263 (2014).","journal-title":"Haematologica"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0137-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0137-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0137-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:38:20Z","timestamp":1671536300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0137-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,5]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11]]}},"alternative-id":["137"],"URL":"https:\/\/doi.org\/10.1038\/s41408-018-0137-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,5]]},"assertion":[{"value":"25 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"101"}}